CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 61 enrolled
Drug / intervention
sulindac +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00368927
NCT00368927Phase 2Completed
CompareCT.gov

Randomized, Phase IIb Trial of Sulindac in Smokers With Bronchial Dysplasia

National Cancer Institute (NCI)·interventional·Posted Aug 29, 2006·Updated May 23, 2014

In Brief

A Phase 2 clinical trial evaluating sulindac and placebo for Precancerous Condition and 2 related conditions. Completed, enrolled 61 participants across 6 sites in 2 countries.

Detailed Summary

This randomized phase II trial is studying sulindac to see how well it works compared to a placebo in preventing lung cancer in current or former smokers with bronchial dysplasia. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of sulindac may prevent lung cancer from forming in patients with bronchial dysplasia. It is not yet known whether sulindac is more effective than a placebo in preventing lung cancer in patients with bronchial dysplasia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrecancerous Condition, Stage I Non-small Cell Lung Cancer, Tobacco Use Disorder
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 29, 2006
Enrollment StartAug 1, 2006
Primary CompletionMay 1, 2010
Study CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 19.8 years ago

Interventions

sulindacdrug

Given orally

placeboother

Given orally